AstraZeneca, Durvalumab
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab for its sale and distribution.
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges
This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central
AstraZeneca India gets CDSCO nod for its chemotherapy drug additional indications
According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.
AstraZeneca Pharma Gets Approval To Import And Distribute Durvalumab For Cancer Treatment
This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment afterward.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.
AstraZeneca Pharma gets nod to launch cancer drug durvalumab in India
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by durvalumab monotherapy post-surgery. Shares of Astrazeneca Pharma India Ltd ended at ₹6,
Medscape6d
'One of the Most Impactful' ESMO Studies: Durvalumab in Muscle-Invasive Bladder Cancer
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...
AstraZeneca Pharma shares in focus on CDSCO permission
The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...
Adjuvant durvalumab extends survival in small cell lung cancer
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...
Astrazenenca Pharma gets CDSCO nod to import Durvalumab solutions
Astrazeneca Pharma India said that it has received permission from Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab solutions (IMFINZI) in India.
Medscape9d
No DFS Benefit With Adjuvant Durvalumab in Early NSCLC
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...